Stock Market

Do Regulatory And Drug-Pricing Worries Mark The End Of Biotech’s Heyday?

The prospect of tighter regulation of the sector (particularly when it comes to mergers and drug approvals) and drug-pricing reform, as well as rising interest rates, have created a “perfect storm” bearing down on biotech stocks. As a result, after seeing massive gains in 2020, biotech stocks have pulled back. Do biotech investors have reason to worry, or is biotech’s… 

Behind On COVID, This Immunology Stock’s Real Value Could Come From Another Product In Its Pipeline

Despite its focus on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, the clinical-stage company featured in today’s article is woefully behind the likes of Pfizer, Moderna, Johnson & Johnson and AstraZeneca when it comes to its COVID-19 product – its lead product. But the real value for this company may come from another product… 

As The Regulatory Environment For Biotech Changes, These 6 Pharma Stocks Have Been Downgraded

With new leadership at the federal agencies that oversee the drug industry, a top Wall Street analyst is warning that the biotech industry and biotech investors “will need to adjust to a different regulatory environment to the one they have enjoyed for the last 5 years” – and has downgraded six pharma stocks due, in part, to the prospect of… 

Stock Picks – And Disruptive Sectors – From The Best Stock Picker Of 2020

Thanks to her bet on disruptive DNA, Bloomberg named ARK Investment Management’s Cathie Wood the best stock picker of 2020. What does Wood believe are going to be the most disruptive sectors going forward, and what specific companies are working on truly disruptive technologies with the potential to change the course of history?  For more – including a look at… 

Top Q2 Ideas For Growth Investors With Some Risk Tolerance

“These five top stocks are all on the BofA Securities US 1 list of top picks. They all are very prominent in their respective silos in the financial and health care sectors, and all are great second-quarter ideas for growth investors with a little bit of risk tolerance looking to rotate capital,” says the author of today’s article of the… 

These 3 Stocks Meet The Profile For “Monster Growth”

When it comes to creating a useful profile for monster growth stocks, the author of today’s article lays out the following criteria: “gangbusters gains, Buy ratings from the Wall Street analyst corps, and considerable upside for the coming year.” With that, he proceeds to highlight three stocks that meet the profile for monster growth, including one that “puts a different… 

Why This Antibody Discovery Company May Be “One Of The Best Held Secrets In The Biotech Landscape”

“Far from a dead company, this may be one of the best held secrets in the biotech landscape,” declares the author of today’s article of the little-followed biotechnology company they highlight: an “antibody discovery company that could have the potential to revolutionize the process for discovering and rapidly advancing new therapies.” For more, CLICK HERE.

The Best COVID Vaccine Stocks For Different Investing Styles

Just as certain COVID-19 vaccines may be better suited for certain groups of people, certain COVID-19 vaccine stocks may be better suited for different investing styles. So, of the six leaders or potential leaders in the U.S. COVID-19 vaccine space right now, which may be the best pick for conservative investors and which may be the best pick for aggressive… 

A Short Biotech Idea

The small-cap biotech company featured in today’s article experienced a remarkable rally over the last few months. However, with the FDA having just approved its most advanced asset, a treatment for ADHD, the author believes that this “exhausts the company’s largest catalyst, and [they] do not see any material new catalysts any time soon.” With that, and with doubts about…